Design for the EMA [Regulatives / Guidelines]

posted by ryraman2661 – India, 2023-05-15 15:03 (25 d 05:58 ago) – Posting: # 23554
Views: 393

Dear Members,

I have one point to be discussed in the forum.

For Bioequivalence studies for EU submission, can we compare capsules VS tablets of same drug, and same strength.

If yes, whether both Cmax and AUC (total) to be included in the criteria? or we can compare only AUC (total).
What are the others points to be taken care.

Members can give their opinion.



Edit: Subject line changed; see also this post #2. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,627 posts in 4,743 threads, 1,613 registered users;
24 visitors (0 registered, 24 guests [including 7 identified bots]).
Forum time: 21:01 CEST (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz